Dr Reddy's looks beyond oral forms as US generics lift Q1
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories reported a 12% increase in revenues to INR28.4bn ($478m) for the first quarter ended 30 June, buoyed by growth in the generics business in the US and some emerging markets, though Europe weighed on the gains.